FDA denies Teva's 7th petition to stop generic Copaxone

The FDA, for the seventh time, has denied a citizen petition from Israeli drug maker Teva requesting US regulators not approve an abbreviated new drug application (ANDA) that references the company's multiple sclerosis (MS) drug Copaxone (glatiramer acetate injection) unless certain conditions are satisfied.

The FDA, for the seventh time, has denied a citizen petition from Israeli drug maker Teva requesting US regulators not approve an abbreviated new drug application (ANDA) that references the company's multiple sclerosis (MS) drug Copaxone (glatiramer acetate injection) unless certain conditions are satisfied.

The FDA told Teva the agency would not comment on the approvability of any application for any glatiramer acetate injection...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.